Real-time enrollment status for this neuroendocrine carcinoma metastatic clinical trial
Current Status
Recruiting
Checked: July 18, 2026 at 1:16 AM UTC
| NCT Number | NCT07114939 |
| Recruiting Status | Recruiting |
| Condition | Neuroendocrine Carcinoma Metastatic |
| Phase | PHASE1 |
| Target Enrollment | 12 participants |
| Active Locations | 1 sites in the US |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Last Updated on CT.gov | February 2, 2026 (Feb 2, 2026) |
As of July 18, 2026: Clinical trial NCT07114939 is currently recruiting participants. This phase1 study for neuroendocrine carcinoma metastatic is actively seeking new participants at 1 location across the United States. The study is sponsored by Abramson Cancer Center at Penn Medicine. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07114939 is actively recruiting participants as of July 18, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 1 location in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07114939 was last updated Feb 2, 2026 (February 2, 2026). HelloStudys verifies this status automatically.